KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Payables (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Payables for 16 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 28.5% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 28.5%, and an annual FY2024 reading of $2.1 million, down 32.11% over the prior year.
  • Payables was $2.0 million for Q3 2025 at TherapeuticsMD, up from $1.6 million in the prior quarter.
  • Across five years, Payables topped out at $20.8 million in Q1 2022 and bottomed at $696000.0 in Q3 2023.
  • Average Payables over 5 years is $7.9 million, with a median of $3.1 million recorded in 2023.
  • The sharpest move saw Payables soared 458.73% in 2022, then crashed 94.8% in 2023.
  • Year by year, Payables stood at $3.4 million in 2021, then skyrocketed by 458.73% to $18.8 million in 2022, then tumbled by 83.38% to $3.1 million in 2023, then crashed by 32.11% to $2.1 million in 2024, then dropped by 5.27% to $2.0 million in 2025.
  • Business Quant data shows Payables for TXMD at $2.0 million in Q3 2025, $1.6 million in Q2 2025, and $1.8 million in Q1 2025.